11 /100
LOW RISK
Score updated Jul 14, 2026

SUPN — Supernus Pharmaceuticals, Inc. Dilution Risk Tracker

Track SUPN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SUPN — Get alerts when the score changes →

As of July 14, 2026, Supernus Pharmaceuticals, Inc. (SUPN) has a DilutionWatch DilutionScore of 11/100, rated LOW dilution risk. Supernus Pharmaceuticals, Inc. has a market capitalization of $2.68B, 58.04M shares outstanding, 331 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
0
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for SUPN.
🔔 Track SUPN — Get forecast alerts →

💹 Market Data

Market Cap$2.68B
Shares Outstanding58.04M
Float52.12M
Cash$553.08M
Debt$401.44M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 12.7% shares (2026Q1 vs prior)
331 institutional holders · 65.87M shares
#1 BlackRock, Inc. 8.80M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 4.93M shares
#3 MILLENNIUM MANAGEMENT LLC 3.32M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest7.14M
Days to Cover7.0
% of Float13.7%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2023
xbrl XBRL CONVERTIBLE Dec 31, 2022
4 INSIDER TRANSACTION Mar 18, 2026
4 INSIDER TRANSACTION Mar 16, 2026
4 INSIDER TRANSACTION Mar 16, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for SUPN Shareholders

Supernus Pharmaceuticals, Inc. (SUPN) has a DilutionScore of 11/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for SUPN shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for SUPN in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for SUPN alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track SUPN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SUPN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for SUPN
📊 SUPN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 SUPN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.